• i_mail

© Copyright Morphocell Technologies Inc 2018

TRANSFORMING THE TREATMENT OF LIVER DISEASE

Morphocell Technologies is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues aimed at treating liver diseases.

ReLiver™​

Morphocell Technologies’ ReLiver™ is an engineered liver tissue that performs like the human liver.

Morphocell Technologies is developing ReLiver™ into 3 different products: 

ReLiver™ELT

An implantable device capable of restoring liver functions in patients with acute and acute-on-chronic liver failure.  ReLiver™ELT is already in advanced pre-clinical assessment 

ReLiver™BALD

An extracorporeal bio-artificial liver device aimed at treating not only patients with acute, but also the tens of millions of patients with chronic liver

ReLiver™Assay

An in vitro assay for next-generation drug discovery.  As a more representative model of the human liver, ReLiver™Assay helps reducing drug failures in the clinical phases.

Acute Liver Failure

 

  • Qualifies as a rare disease with an incidence of <1/100,000 per year​​

  • Liver transplantation is the only cure (62% overall survival, <50% for infants​
     

  • Acute liver failure accounts for >1000 deaths/year in the United States​
     

  • Up to 80% of patients with ALF could avoid transplantation if temporary replacement of liver functions could be assured while their own liver regenerates.

Through cutting-edge approaches of tissue engineering, Morphocell Technologies is developing revolutionary products targeting currently untreatable liver diseases.

Deaths caused by liver disease worldwide

>1 MILLION/year

Acute liver failure: survival rate without liver transplant

<50%

NEWS
CONTACT US

info@morphocell.com

+1 (514) 345 4931 ext. 7879

 

c/o CHU Sainte-Justine Research Center

3175 Ch. Côte-Sainte-Catherine

Montreal, QC, H3T 1C5

Canada